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Abstract. Methyl-L-DOPA, an antihypertensive agent, has
significant in vitro activity against a variety of atypical
mycobacteria such as the Mycobacterium avium complex, M.
scrofulaceum, M. xenopi and M. marinum, and rare
pathogens like M. fortuitum. In the present investigation, the
screening of the in vitro activity was further extended by
testing the in vitro activity against a total of 53 different
strains of mycobacteria, including 34 clinical isolates of both
drug-sensitive and drug-resistant Mycobacterium tuberculosis.
Most of the strains were inhibited at 10-25 Ìg/mL
concentrations of the drug. When methyl-L-DOPA was
injected into male mice at a concentration of 10 Ìg/g body
weight (20 g each), methyl-L-DOPA significantly protected
them when challenged with a 50 median lethal dose of M.
tuberculosis H37Rv102. According to the ¯
2test, the in vivo
data were highly significant (p<0.01).
Tuberculosis is still a leading cause of death among
infections with a single etiology and one-third of the world
population is latently infected with Mycobacterium
tuberculosis. Both the increase in AIDS-associated infections
and recent outbreaks of diseases sustained by multidrug-
resistant (MDR) strains of M. tuberculosis should motivate
the development of new, more effective antitubercular drugs
for alternative treatments. Several tuberculosis control trials
and MDR reversals are aimed at preventing the spread of
tuberculosis and MDR-tuberculosis infections. Interestingly,
the new microcapsule administration with drug-loaded
microspheres or some drug combination therapies have
increased the therapeutic efficacy and reduced the toxicity
of the administered antimycobacterial drugs. Despite such
progress, it is necessary to develop more potent drugs for the
MDR reversal treatment of mycobacteriosis. Antimicrobial
agents, such as artificial chemicals with diverse
pharmacological effects, have also revealed powerful efficacy
against a great variety of Gram-positive and Gram-negative
genera, such as: (i) antihistamines [diphenhydramine,
bromodiphenhydramine (1), methdilazine (2) promethazine
(3)], (ii) psychotropics [promazine (4), fluphenazine (5) and
trifluoperazine (6)], (iii) antihypertensives [methyl-L-DOPA
(7)], (iv) anti-inflammatory drug [diclofenac (8, 9)] and (v)
cardiovascular drugs [oxyfedrine (10), amlodipine (11)]. These
chemotherapeutic agents have been grouped together and are
termed "non-antibiotics" (12). Some non-antibiotics, such as
chlorpromazine (13), levopromazine and promethazine (14),
promazine and desipramine (15), trifluoperazine (16),
methdilazine (17), thioridazine (18) and other phenothiazines
(19), are also antitubercular. Based on these findings, methyl-
L-DOPA, a non-antibiotic, was tested against different
strains of mycobacteria. In vitro observations were further
confirmed by in vivo protection tests in mice against many
strains of mycobacteria.
Materials and Methods
Chemicals. The chemicals were obtained as pure dry powders
from their respective manufacturers in India, as follows: methyl-
L-DOPA (m-L-DOPA) from Dolphin Laboratories, rifampicin
(Rf) from Hindustan Ciba Geigy, streptomycin (Sm) from
Sarabhai Chemicals, ethambutol (Eb) from Lyka Laboratories
and isonicotinic acid hydrazide (INH) from Glaxo Laboratories.
All chemicals were stored at 4ÆC.
Bacteria. Fifty-three strains of mycobacteria were tested. The
strains and their sources are given in Table I. The strains were
identified by radiometric method (BACTEC 460) and
biochemical tests (Niacin, Nitrate, Urease, Catalase, Tween 80,
Tellurite and 5% NaCl tests).
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Media. Kirchner’s Liquid Medium (KLM) (20) was used to grow
and suspend the organisms. The solid medium was Lowenstein
Jensen Medium (LJM), prepared as described by the
International Union Against Tuberculosis and Lung Diseases
(IUATLD), 1955 (21).
Preparation of inocula for susceptibility tests. The bacteria were
first grown in KLM. The inoculum was prepared by homogenizing
the KLM culture with glass beads, spinning down the larger
particles, and matching the supernatant against McFarland’s
standard (22).
Determination of minimum inhibitory concentration (MIC) of
antibiotics / non-antibiotics against different strains of mycobacteria.
The MICs of the test strains were determined by tube dilution
method (23). In this test, MIC represented the lowest
concentration of an antibiotic or a non-antibiotic that completely
inhibited the growth of the organism. The MIC of a given
antibiotic / non-antibiotic for a test strain was compared with its
modal MIC for the control strains, and the resistance ratio was
expressed as MIC for the test strain / modal MIC for the control
strains. A ratio of 4 or more for a test strain indicated its
resistance to a given drug. The drugs such as streptomycin,
rifampicin, INH and ethambutol were used at concentrations of 0,
0.25, 0.5, 1, 2, 4 and 8 Ìg/mL. The resistant strains were further
processed for determining the resistant breakpoint by using 8, 16,
32, 64 and 128 Ìg/mL of the drug in LJM. The following drugs had
MIC levels of the primary antitubercular drugs indicating
resistance: streptomycin (Sm) ≥32 Ìg/mL, isoniazid (INH) 
≥1 Ìg/mL, rifampicin (Rf) ≥128 Ìg/mL and ethambutol (Eb) 
≥8 Ìg/mL. Likewise, the MIC of methyl-L-DOPA with respect to
the different strains of mycobacteria was determined by using 0,
5, 10, 12.5, 15, 20, 25 and 50 Ìg/mL concentrations. The amount of
inoculum used to inoculate each tube was 0.01 mL. Incubation was
at 37ÆC for 10-20 days as required. The in vitro screening was
in vivo 19: 539-546 (2005)
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Table I. Source of mycobacterial strains tested.
Mycobacteria Source
Reference strains
M. tuberculosis H37 Rv102, H37Ra16 Tuberculosis Research Center, 
Chennai, ICMR, Govt. of India
M. marinum NCTC 2273, M. scrofulaceum 1302, M. scrofulaceum 1323, Central  JALMA Institute 
M. gordonae 1324, M. flavescens 1451, M. xenopi 10, M. xenopi 160, for Leprosy ICMR, Agra, India
M. avium 724, M. avium NCTC 8551, M. intracellulare 1406, M. terrae 1450, 
M. terrae 1540, M. trivate 1453, M. smegmatis 798, M. smegmatis 1546, 
M. fortuitum 1529, M. phlei L1
Clinical strains
M. tuberculosis Bajaj, J15, N23, M. tuberculosis 90657, 905358, 905574, Tuberculosis Research Centre,
906909, 910708, 911053, 11337, 911447, 911454, 911677, 911831, 911884, Chennai, India
911928, 912042, 912056, 912073, 912234, 912359, 912447
M. tuberculosis K1, K2, M. tuberculosis BTA 1(10376), BTA 2 (10378), K.S. Roy TB Hospital, Calcutta Bengal 
BTA 3 (1811), BTA 4 (1813), BTA 5 (1824), BTA 6 (1831), BTA 7 (1834), Tuberculosis Association (BTA),
BTA 8 (1854), BTA 9 (1856), BTA 10 (1864) Calcutta, India
Table II. Antibiogram patterns of different strains of mycobacteria.
Mycobateria Sensitivity of primary antituberculous drugs
INH Rf Sm Eb
M. tuberculosis (24) S S S S
M. tuberculosis (12) R R S S
M. tuberculosis (4) R S S S
M. tuberculosis (1) S R S S
M. tuberculosis (1) R S R S
M. tuberculosis (1) R S S R
M. tuberculosis (1) R R R S
M. tuberculosis (1) R R S R
M. tuberculosis (1) R S R R
M. tuberculosis (7) R R R R
S, sensitive; R, resistant; INH, isoniazid; Rf, rifampicin; Sm,
streptomycin; Eb, ethambutol.
carried out in triplicate for most of the organisms, and five times
for the potent ones, and the mean values of the MIC were
indicated. For some selected strains, the drug was tested in
concentrations ±2 of its MIC value, in order to find out its mean
± standard deviation values with respect to these organisms.
Animal experiments. Inbred Swiss Albino male mice (ca. 18-20
g) were maintained in the animal house under standard
conditions at 21±1ÆC and 50-60% relative humidity, with a
photoperiod of 14:10 hours of light-darkness. Water and a dry
pellet diet were given ad libitum. M. tuberculosis H37Rv102 was
used as the test bacterium, which was naturally virulent to mice.
The median lethal dose (MLD / LD50) of the strain (after
repeated passage through mice) was determined by using graded
challenges in batches of mice and recording the mortality up to
30 days. The LD50 was not affected by the freeze-drying and
reconstitution. Reproducibility of the challenge dose was
ensured by standardizing its optical density at 640 nm in a Klett-
Summerson colorimeter to obtain the desired colony forming
units (cfu) on KLM. 
Systemic infections were produced in 20 mice. Each mouse was
administered intraperitoneally (i.p.) 0.05 mL of a suspension
(containing 0.5 mg homogenized KLM culture deposit,
representing < 9 x 109 cfu) (24); of the 20 animals, 10 mice were
administered m-L-DOPA (dose 10 Ìg/g body weight/day x 6
weeks), while the other 10 mice did not receive any drug and
served as the control. The viscera from the animals autopsied 6
weeks after infection were obtained, taking strict precautions
regarding sterility, and examined for macroscopic lesions of
systemic infections, e.g., tubercles and caseation, both for the
treated and untreated groups (25). Portions of each organ were
processed for histological study of the lesions, while the
remainders were homogenized aseptically in sterile glass
homogenizers in saline, examined under the microscope as
stained smears (Hematoxylin and Eosin, as well as Ziehl-Neelsen
stains) for the presence of acid fast bacilli (AFB)/ and
contaminants, and inoculated onto nutrient/blood agar plates to
determine rapid growth, if any. Sterile specimens (as well as
contaminated specimens after adequate decontamination by
Petrov’s method) were plated out on LJM in 0.1 mL amounts and
examined for growth of the infecting M. tuberculosis. The growth
was confirmed by radiometric method.
Results
Minimum inhibitory concentration (MIC) of INH, Sm, Rf,
Eb and m-L-DOPA against different strains of mycobacteria.
Nineteen reference strains including Mycobacterium
tuberculosis H37Rv102, H37Ra16, M. phlei L1, M. avium
complex, M. scrofulaceum, M. xenopi, M. marinum and M.
kansasii, and rare pathogens like M. fortuitum, were
sensitive to all four conventional antimycobacterial drugs.
Among 34 clinical strains of mycobacteria, 5 strains were
sensitive to all these 4 drugs, 12 strains showed resistance
to both INH and Rf, 4 strains were found to be resistant
to INH and one strain to Rf. Resistance to both Sm and
INH, or INH and Eb was noticed in one strain each.
Similarly, resistance to 3 drugs, either INH, Rf and Eb, or
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Table III. Antimycobacterial profile of methyl-L-DOPA.
Bacterial strain MIC (Ìg/mL) Mean±SD
Sensitive strains
M. fortuitum 1529, M. scrofulaceum 1323, M. scrofulaceum 1302, 10 10±0.82
M. flavescens 1541, M. trivate 1453, M. phlei L1
M. smegmatis 798, M. smegmatis 1546, M. xenopi 160, M. avium 724, 12.5 12.5±0.41
M. avium NCTC 8551, M. intracellulare 1406, M. marinum NCTC 2273
Mycobacterium tuberculosis H37 Rv102, M. marinum 50, M. gordonae 1324, 15 15±1.63
M. terrae 1450, M. terrae 1540, M. tuberculosis Bajaj, J15, N23, 
H37Ra16, K1, 911928, 912447, 912234, 912359, 906909
Multidrug-resistant
M. tuberculosis BTA1, BTA2, BTA3, BTA4, BTA5, BTA6, BTA7, 20 20±2.45
BTA8, BTA9, BTA10, 995574, 905358, 910657
Polydrug-resistant
M. tuberculosis 911454, 912042, 911831, 911447, 911677, 910708, 25 25±1.41
911884, 912056, 911053, 911337, 912073
INH, Rf and Sm, or INH, Sm and Eb, was noted in one
strain each. Finally, 7 strains were resistant to all the 4
drugs (Table II). The MIC of m-L-DOPA with respect to
53 strains of mycobacteria tested is given in Table III. The
MIC of m-L-DOPA was much higher than the MIC of the
conventional antimycobacterial drugs (Sm, Rf, INH, Eb).
Among 53 strains of mycobacteria tested, 6 strains (M.
fortuitum 1529, M. scrofulaceum 1323, M. scrofulaceum
1302, M. flavescens 1541, M. trivate 1453, M. phlei L1) were
inhibited by m-L-DOPA at 10 Ìg/ml, while 7 strains (M.
smegmatis 798, M. smegmatis 1546, M. xenopi 160, M.
avium 724, M. avium NCTC 8551, M. intracellulare 1406
and M. marinum NCTC 2273) were inhibited at 12.5 Ìg/mL
of m-L-DOPA. These 13 strains were highly sensitive with
respect to conventional antitubercular drugs. Sixteen
strains (M. marinum 50, M. gordonae 1324, M. terrae 1450,
M. terrae 1540, M. tuberculosis Bajaj, J15, N23, H37 Rv102,
H37Ra16, K1, K2, 911928, 912447, 912234, 912359 and
906909) were inhibited at 15 Ìg/mL of m-L-DOPA.
Thirteen strains (M. tuberculosis BTA1, BTA2, BTA3,
BTA4, BTA5, BTA6, BTA7, BTA8, BTA9, BTA 10,
905574, 905358 and 910657) were found to be MDR. They
were inhibited by m-L-DOPA at 20 Ìg/mL. Finally, M.
tuberculosis 912042, 911831, 911447, 911677, 911454,
910708, 911884, 912056, 911053, 911337 and 912073 were
inhibited by m-L-DOPA at 25 Ìg/mL. These strains were
polydrug-resistant. The susceptible strains such as M.
tuberculosis H37Rv102 were inhibited at lower doses of
conventional antitubercular agents (0.5 to 2 Ìg/mL), while
the single-, poly- and multidrug-resistant clinical isolates
(M. tuberculosis 906909, M. tuberculosis 911454, M.
tuberculosis BTA8 and others) were inhibited at much
higher concentrations, and some were even resistant. The
MIC of m-L-DOPA against M. tuberculosis H37Rv102 was
15 Ìg/mL, while it was 25 Ìg/mL for the drug-resistant
strains. The MIC values of m-L-DOPA in terms of
mean±standard deviation with respect to 5 strains (M.
fortuitum 1529, M. smegmatis 798, M. tuberculosis
H37Rv102, M. tuberculosis BTA1 and M. tuberculosis
911454) are given in Table πππ. It was noticed that even the
multidrug-resistant strains were susceptible to m-L-DOPA,
although at a higher concentration (25 Ìg/mL).
In vivo assessment. An analysis of the results given in Table
IV showed that, in the untreated group, out of a total of
10 animals, 8 developed minute tubercles in the liver, 5 in
the spleen, 5 in the lungs and 9 in the peritoneum and
intestines; in the liver of 3 animals and in the spleen,
peritoneum and intestines each in one animal, microscopic
necrosis was detected, which suggested caseation. From
centrifuged deposits (for 100 fields) of tissue homogenates,
smears for acid-fast bacilli (AFB) were prepared by Z-N
stain; such smears showed all 10 mice to be smear-positive
at the time of autopsy, suggestive of successful infection in
these animals. However, in macroscopic examination of
the treated group (10 animals), minute tubercles were seen
in vivo 19: 539-546 (2005)
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Table IV. Evidence of protection by methyl-L-DOPAa against M. tuberculosis H37 Rv 102b infection in mice.
Treatment Liver Spleen Peritoneum / Lung Cumulative Recovery of H37Rv102 in
Intestine value smears culture
Untreated (10)
Smears AFB (+) 10/10 10/10 10/10 10/10 40/40
Tubercles 8 5 9 5 27 10c 5
Caseation 3 1 1 0 5
Treated (10)
Smears AFB (+) 0/10 2/10 2/10 0/10 4/40
Tubercles 2 4 3 0 9 4d 1
Caseation 0 0 0 0 0
Untreated: did not receive methyl-L-DOPA.
Treated: received methyl-L-DOPA.
a 10 Ìg/g body weight/day.
b 4.5 x 109 CFU/mouse intraperitoneally.
c from at least one viscera of 10 animals, all viscera did not yield (+) culture; the viable counts (CFU) varied from 103 to 106/mL.
d only from 4 animals, recovery from even a single organ being counted as positive, other organs did not yield any growth;CFU 101-103/mL in the
positive samples.
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to be present in 2 liver specimens, in 4 samples of spleen,
and in the peritoneum, as well as in the intestine of each of
3 animals, but no tubercle was detected in the lungs. AFB
was present only in 4 cases, as revealed by Z-N-stained
smears. M. tuberculosis H37Rv102 could actually be
recovered on subculture (as confirmed by BACTEC test)
in only one animal of the treated group, in contrast to 5
animals of the untreated group, which was statistically
significant (p<0.01). There was a considerable decrease in
the number of infiltrations in infected mice treated with
methyl-L-DOPA, as compared to the untreated animals
(controls), as observed in the histopathological sections of
the lungs (Figure 1a, 1b, 1c).
Discussion
Methyl-L-DOPA, both an antihypertensive and
Parkinson’s disease drug, was found to possess conspicuous
antibacterial activity on testing against 405 strains of
bacteria including a large number of Gram-positive and
Gram-negative genera. The MIC of m-L-DOPA ranged
from 10-200 Ìg/mL. This bacteriostatic agent could also
offer significant protection to mice when challenged with a
virulent bacterium (7).
In the present study, m-L-DOPA showed a noteworthy
antitubercular activity against diverse mycobacteria. The MIC
of m-L-DOPA ranged from concentrations of 10-25 Ìg/mL
with respect to most strains tested. Many of the
antimycobacterial non-antibiotics reported so far have
shown in vitro MIC values ranging from 10 to 25 Ìg/mL,
which seems to be in accordance with that of m-L-DOPA.
Phenothiazines, such as chlorpromazine (13), promethazine
(14) and thioridazine (18), have been shown to have in vitro
activity against clinical strains of M. tuberculosis. This
activity required concentrations that are beyond those that
are clinically achievable (i.e. 1 Ìg/mL). Thus, a clinically
acceptable administration dosage for a tuberculosis patient
might contribute to an inhibitory effect when the in vitro
dosages are close to the in situ intracellular doses. This
suggests that MDR reversal drugs such as m-L-DOPA
could be clinically used as very effective adjuvants in a new
regimen for the management of freshly diagnosed
tuberculosis. 
In the animal tests with M. tuberculosis H37Rv102 in
mice, several minute tubercles were observed in the liver,
spleen, lungs, peritoneum and intestines of infected mice.
However, m-L-DOPA administration significantly
protected the mice (Table IV).
In spite of the toxic effect of m-L-DOPA, it was well
tolerated and could protect the mice for the entire period of
6 weeks of daily i.p. administration at the dose of 10 Ìg/g
body weight. Because m-L-DOPA is a precursor, which is
metabolized in the brain to the active form, m-L-DOPA
might play a primary role after the precursor has been
metabolized and activated. When administered orally,
methyl-L-DOPA is absorbed by an active amino acid
transporter. The peak effective plasma concentration was
reached after 2 to 3 hours. Methyl-L-DOPA is distributed in
a relatively small apparent volume (0.4 L/kg) and is
eliminated with a half-life of about 2 hours. The transport of
m-L-DOPA into the central nervous system (CNS) is
apparently also an active process. Methyl-L-DOPA is
excreted in the same way as other different kinds of
metabolites such as methyldopamine, methylnorepinephrine
and o-methylated products of these catecholamines. The rate
of de-esterification of m-L-DOPA is variable among
patients, and an intravenous m-L-DOPA administration
might deliver less m-L-DOPA to the circulation when
compared to an oral administration (26).
The above results of preliminary screening showed that
m-L-DOPA could be used as a starting material for further
new and safe drugs with increased antimycobacterial and
reduced antihypertensive activity.
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